Bell's Palsy

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

[Comment] CHOP intensification: not yet state of the art

Addition of the anti-CD20 agent rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy represents the most important progress in the treatment of diffuse large B-c...

CHOP collaborates with Pfizer's Centers for Therapeutic Innovation to speed pediatric R & D

The Children's Hospital of Philadelphia (CHOP) and Pfizer, Inc., are joining forces with the goal of translating biomedical discoveries into novel treatments. CHOP is announcing its participation in t...

The Children's Hospital of Philadelphia Play Area Opens at King of Prussia Mall

CHOP-Sponsored Play Area Serves Families in Surrounding Community KING OF PRUSSIA, Pa., Feb. 15, 2013 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia (CHOP) today celebrated the ope...

CHOP Celebrates 50 Years of N/IICU Care

The Children's Hospital of Philadelphia (CHOP) celebrated the 50th anniversary of the opening of the Harriet and Ronald Lassin Newborn/Infant Intensive Care Unit (N/IICU), the nation's first surgical...

CHOP Collaborates With Pfizer’s Centers For Therapeutic Innovation To Speed Pediatric Research & Development

Dateline City:  Philadelphia, PA The Children’s Hospital of Philadelphia (CHOP) and Pfizer Inc. are joining forces with the goal o...

CHOP’s Center for Autism Research receives five-year grant as an NIH Autism Center of Excellence

The Center for Autism Research at The Children's Hospital of Philadelphia (CHOP) announced today that it will continue its research to identify early signs of autism spectrum disorders (ASD) through a...

CHOP collaborates with Pfizer's Centers for Therapeutic Innovation to speed pediatric R & D

(Children's Hospital of Philadelphia) The Children's Hospital of Philadelphia (CHOP) and Pfizer, Inc., are joining forces with the goal of translating biomedical discoveries into novel treatments. CHO...

The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.

The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell ly...

Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial.

PURPOSE Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma. Granulocyte colony-stimu...

CHOP deletion does not impact the development of diabetes but suppresses the early production of insulin autoantibody in the NOD mouse.

C/EBP homologous protein (CHOP) has been proposed as a key transcription factor for endoplasmic reticulum (ER) stress-mediated β-cell death induced by inflammatory cytokines in vitro. However, the co...

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patien...

Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.

The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicin-containing chemot...